Everolimus is an oral inhibitor of the mammalian target of rapamycin (mTOR) with anti-cancer activity in multiple tumor types, including well-differentiated neuroendocrine neoplasms, named neuroendocrine tumors (NETs). The gene discussed is MTOR; the disease is neoplasm.